The Brash Strategy That Made Vivek Ramaswamy a Fortune
Updated Sept. 9, 2023 10:51 am ETVivek Ramaswamy was a novice biotech entrepreneur in 2016 with no advanced medical training ...
Read moreUpdated Sept. 9, 2023 10:51 am ETVivek Ramaswamy was a novice biotech entrepreneur in 2016 with no advanced medical training ...
Read moreText sizing Moderna gave an update on its portfolio of vaccines. Getty Illustrations or photos Moderna claimed Tuesday an unbiased ...
Read moreVirtually two years following biotechnology shares began to tumble, executives at modest and midsize corporations in the room are lastly ...
Read moreThe S&P Dividend Aristocrats deserve more coverage. Those are companies that have raised their dividend payouts consistently over the years ...
Read moreRegeneron Pharmaceuticals inventory was tumbling just after the medication maker described reduced product sales of its Eylea vaccine than Wall ...
Read moreMost cancers-screening corporation Exact Sciences hadn’t anticipated to report income earnings until this year’s September quarter. But the seller of ...
Read moreAstraZeneca agreed to acquire U.S. biotech firm CinCor Pharma in a deal perhaps valued at $1.8 billion, the British pharmaceutical ...
Read moreOcugen Inc. stock OCGN, +.78% rallied 16% in premarket trade Monday, following the biopharma firm introduced positive success in a ...
Read moreWe've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. We've detected ...
Read moreAstraZeneca agreed to invest in U.S. biotech enterprise CinCor Pharma in a offer perhaps valued at $1.8 billion, the British ...
Read moreEmail Contact: souhaib@trendswide.com